A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants with Uncontrolled Hypertension

Exclusion Criteria

• - Mean seated diastolic blood pressure (DBP) on AOBPM >=110 mmHg at randomization.
• - Prior treatment (within the 4 weeks before screening) with angiotensin receptor Blocker (ARBs) and angiotensin converting enzyme inhibitor (ACEIs) (both taken simultaneously).
• - Serum sodium (Na+) level < 135 millimole per liter (mmol/L) at screening, determined as per central laboratory.
• - New York heart association functional heart failure (HF) Class IV at screening.
• - Planned percutaneous coronary intervention/coronary artery bypass grafting or percutaneous coronary intervention/coronary artery bypass grafting done within 6 months prior to screening.
• - Uncontrolled diabetes with glycated haemoglobin (HbA1c) > 10.0% (86 mmol/mol) at screening.
• - Fridericia’s corrected QT (QTcF) value > 470 milliseconds (ms) at screening, unless having a pacemaker.
• - Heart rate < 45 or > 110 beats/min in a resting position, as per vital signs assessment.